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Abstract
This review is concerned with a number of recent publications that contribute to
current thinking on the pathogenesis of spondyloarthritis. The areas covered
include the lymphocyte population in the enthesis, which is thought to drive
enthesitis, and hence clinical manifestations. The debate on how HLA-B27 is
implicated in inflammation is also considered, together with recent and
contradictory evidence on the effects of the peptide-trimming enzyme ERAP1
on B27 expression and hence susceptibility to spondylitis. Lastly, a recent
report on the role of the gut microbiome in an important model of
spondyloarthritis is considered.
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Introduction
A great deal of evidence, particularly from genome-wide associa-
tion studies, has implicated the IL-23–IL-17 cytokine axis in the 
pathogenesis of spondyloarthritis (SpA). These indications have 
been strengthened by the success of therapies targeting these 
cytokines in various forms of SpA: for example, IL-17 blockade in 
ankylosing spondylitis (AS) and anti-IL-12/-23 in psoriatic arthri-
tis. However, in this context, a number of important questions arise, 
and I will deal with three:
1. What kind of IL-23-responsive and IL-17-producing cell drives 
inflammation in SpA, and where is the cell located?
2. How is HLA-B27 implicated in causing inflammation, and how 
does it affect the IL-23–IL-17 axis?
3. What is the stimulus for the excessive production of IL-23 that 
drives the IL-23-responsive pro-inflammatory cell?
A number of recent papers have shed light on these questions or 
raised new points to consider.
The effector cell in SpA pathogenesis
Entheseal T cell populations
When Sherlock, Cua, and colleagues1 over-expressed IL-23 in 
mice (a specific strain, B10.RIII), they noted that this resulted in 
enthesitis. They also discovered that the normal enthesis contains 
a T cell population that expresses the IL-23 receptor (IL-23R) and 
that these cells expand under the influence of excess IL-23. The 
cells comprised an unusual CD3+ T cell subset expressing nei-
ther CD4 nor CD8. This paper was a considerable advance in our 
understanding of SpA pathogenesis and has justifiably received 
a great deal of attention and expectation of confirmative and 
follow-up studies. One such study has now been published and 
has used broadly similar methods to those of Sherlock et al.: 
labelling of specific cell populations by coupling their expres-
sion of molecules of interest (e.g. IL-23R) to a fluorescent pro-
tein (“reporter mice”) so that the cells can be visualised in living 
tissue by two-photon microscopy2. When the authors labelled all 
cells expressing the δ chain of the γδ T cell receptor (TCR) in 
B10.RIII mice, they noted a positive population in entheses 
(Achilles tendon insertion and vertebral bodies). The cells appeared 
to be non-motile, rather like the γδ T cell population that is seen 
in murine skin, where it is believed to perform an immunosur-
veillance function. This population accounted for approximately 
25% of the entheseal T cell population; thus, whilst TCR αβ cells 
were also clearly present in entheses, the proportion of γδ cells 
was very high as compared with other sites such as the spleen, 
where γδ cells represent only 1–2% of T cells. Nevertheless, the 
normal enthesis contained only a few hundred of these cells. 
Importantly, the cells mainly expressed Vγ6 as part of the γδ 
TCR, and such cells have been previously noted to be IL-17 pro-
ducing. Other characteristics also pointed to this capacity, such 
as the expression of CCR6 (the cells described by Sherlock et al. 
were CCR6 negative). Additional experiments aimed to character-
ise the entheseal population further by labelling cells expressing 
the transcription factor required for IL-17 production, RORγt, or, 
as in the Sherlock study, IL-23R. This showed that, whilst cells 
expressing either RORγt or IL-23R were less numerous than 
those expressing TCR γδ (50% and 25% of the numbers, respec-
tively), the γδ cells still accounted for the majority of IL-23R+ 
and IL-17-producing cells. Finally, over-expressing IL-23 using 
the same technique as Sherlock et al. resulted in enthesitis and an 
expansion of the γδ population, and the same expansion was seen 
at other enthesis-like sites in the body known to be involved in 
SpA: the aortic root and the ciliary body of the eye.
How do these findings compare with those previously reported? 
There is agreement that the enthesis in mice contains CD4–
CD8– T cells and that there are both TCRαβ+ and TCRγδ+ 
cells. The new report emphasises the role of a γδ+ subset in 
relation to IL-23R expression (and hence an ability to respond to 
raised IL-23 levels) and therefore IL-17 production. There is cur-
rently no evidence to determine whether TCRγδ or TCRαβ cells 
are principally responsible for enthesitis or indeed whether both 
subsets contribute. Differences in mouse colonies and their gut 
flora might conceivably affect which T cell subset predominates.
The broader question concerns the normal physiologic role of 
entheseal T cells and whether such a population is also found in 
humans. Answers to the latter question are eagerly awaited, but 
the technical difficulties are formidable. There are major differ-
ences between mice and humans in the T cell populations that 
predominate at different anatomical sites – the so-called “resident 
lymphocyte populations”. For instance, murine skin mainly con-
tains a particular subset of TCRγδ cells (Vγ3Vδ1 cells), whereas in 
humans this is absent. Likewise, in the liver, mice have a predomi-
nant resident population of invariant natural killer (NK) T (iNKT) 
cells that recognise bacterial lipids presented by the non-classical 
MHC-like molecule CD1d, whereas human livers have many fewer 
iNKT cells and instead a large population of cells – mucosal- 
associated invariant T cells (MAIT cells) – that recognise cer-
tain bacterial metabolites presented by another MHC class I-like 
molecule, MR13. Whilst in skin and portal tracts the resident 
lymphocyte populations in both species probably detect bacterial 
products as part of their barrier function, this seems unlikely to be 
the case in the enthesis, which would not normally be exposed to 
bacteria. However, even in barrier sites, these resident populations 
can also recognise alternative ligands generated by local tissue 
damage rather than by pathogens. In the enthesis, detection of 
tissue damage would be appropriate, given its function and its 
exposure to mechanical stress. It will be interesting to determine 
whether the resident lymphocyte population in the normal human 
enthesis has a restricted set of receptors geared to the recognition 
of a product of e.g. mechanical stress. The nature of the “antigen” 
or metabolite produced in response to stress and recognised by the 
entheseal population will also be important to determine. However, 
it is also a feature of resident T cell populations that they can be 
activated by cytokines as well as by the entity recognised by their 
invariant receptors; IL-23 has a particular role in this respect.
Factors altering T cell differentiation in SpA
Whilst a cell expressing the transcription factor RORγt is clearly 
implicated in the work on entheseal populations, the role in AS of 
another transcription factor that determines T cell function, Tbet 
(TBX21), has been less clear. A single nucleotide polymorphism 
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(SNP) in the TBX21 gene is associated with increased risk of 
AS, and Lau et al.4 recently showed that AS patients homozygous 
for this SNP had higher levels of Tbet mRNA, though surpris-
ingly this was not the case in healthy controls of the same geno-
type. Whilst this might suggest that inflammation is needed for 
the effects of the SNP on expression levels to be manifest, levels 
in AS patients were independent of disease activity. Proportions of 
Tbet+ cells were also elevated in AS, especially CD8+ cells, and 
levels of expression of Tbet were also higher in these cells. These 
findings are interesting, since it has been postulated, from work 
in a number of models of autoimmunity, that IL-17-producing 
cells are not themselves the pathogenic population in such 
diseases but instead that the critical cells are derived from the 
Th17 subset and express interferon-γ (IFNγ) as well as, or instead 
of, IL-17 (“ex-Th17 cells”). AS patients were shown to have 
increased proportions of cells making both IFNγ and IL-17. This 
differentiation of Th17 to IFNγ-producing cells might require 
Tbet, thus explaining the role of the polymorphism in suscepti-
bility to AS. In keeping with this idea, knockout of the Tbet gene 
in mice alleviated the SpA-like arthritis seen in SKG mice chal-
lenged with fungal antigens (in the form of curdlan). However, 
precisely how Tbet expression favours the emergence of a poten-
tially pathogenic CD8+ T cell population producing both IL-17 
and IFNγ is not yet clear. Whilst Lau et al. cited evidence of Tbet 
inducing IL-23R expression, more recent evidence suggests that 
RORγt is the principal transcription factor required for this and 
that Tbet in fact can inhibit IL-23R expression5. Since IL-23 is 
central to the SpA disease in SKG mice and is also implicated in 
human SpA, with both genetic and therapeutic evidence, this 
paradoxical effect of Tbet on IL-23R expression is puzzling and 
requires further work. Likewise, the expression of Tbet by 
the entheseal populations described above would be worth 
investigating.
How does HLA-B27 influence susceptibility to SpA?
How do ERAP1 polymorphisms interact with B27?
Three main ideas have dominated thinking on how HLA-B27 
exerts its profound effect on susceptibility to SpA. The first, and 
oldest, is the straightforward one of B27 presenting an “arthri-
togenic” (or perhaps “enthesitogenic”) peptide to CD8+ T cells. 
The other two look to unconventional properties of B27. One is 
the tendency of the B27 heavy chain to misfold during synthesis 
in the endoplasmic reticulum (ER) and hence provoke an ER stress 
response, which in turn influences cytokine secretion, particularly 
IL-236. The other is its ability to be expressed on the cell surface as 
dimers/multimers that engage receptors (KIR) on T cells, NK cells, 
and antigen-presenting cells (APCs) and affect their functioning, 
especially by skewing responses towards IL-17 production. It has 
proven difficult to confirm or refute these three hypotheses. The 
discovery that susceptibility to AS is influenced by polymorphisms 
in the ERAP1 molecule, but only in HLA-B27+ subjects, promised 
to shed some light on the issue7. ERAP1 is a protease whose func-
tion is to trim antigenic peptides to appropriate sizes to fit into class 
I MHC molecules. Would the polymorphisms in ERAP1 change 
the repertoire of peptides presented by B27, affect assembly in 
the ER (and hence misfolding), or alter the expression of surface 
multimers? It was reported that alleles of ERAP1 that afforded 
protection from AS showed defective protease function. This 
appeared to be evidence against a role for either ER stress or the 
expression of multimers in SpA pathogenesis, since poorly func-
tioning ERAP1 would be predicted to impair B27 assembly and 
hence increase ER stress. Likewise, poor assembly of B27 with 
optimal peptides might lead to increased expression of unusual 
forms of B27 at the cell surface. Thus, on balance, the observations 
on ERAP1 were taken as evidence in favour of a role for B27 pre-
senting a pathogenic peptide, since inefficient ERAP might avoid 
generation and presentation of such a peptide.
There was, therefore, a good deal of interest when it was reported 
by Reeves et al.8, firstly, that ERAP1 was more polymorphic 
than previously suspected – 13 alleles were described – and,  
furthermore, that when subjects were characterised according  
to the two alleles (co-dominantly expressed) that they inherited, it 
was possible to classify them accurately as AS patients or healthy 
controls. The AS patients had combinations of alleles that were 
defective in their protease activity – either inefficient trimmers 
of peptides or hyper-efficient trimmers. Thus, this study linked  
susceptibility to AS with defective ERAP1 function rather than  
the other way round. Whilst provocative, the findings were based 
on sequencing studies in a fairly small number of AS patients and 
controls (17 and 19, respectively).
Very recently, these findings have been strongly questioned9.  
By examining ERAP1 haplotypes (i.e. ERAP1 alleles with com-
binations of polymorphic amino acids at five positions) in 213 AS 
family trios (71 patients and their parents), supplemented with 
sequencing studies in 48 additional AS patients, Roberts et al. 
found only six haplotypes, with no examples of six of the hap-
lotypes described in the previous study or of nine of the putative 
polymorphisms previously postulated. Only four alleles were 
common. There were no examples of a particular haplotype com-
bination previously suggested to be present in over 50% of AS 
patients. Extending their findings by imputing alleles from SNP 
data available from very large numbers of patients and controls pre-
viously examined in the Immunochip study (4,230 AS cases and  
9,700 controls10) confirmed the finding of four common haplo-
types and noted three other rare ones (<1% population frequency), 
including one suggested in the previous work to be common 
in AS. The major difference between AS patients and controls  
concerned a haplotype containing K528 (instead of R528) present 
in 33% of AS patients versus 27% controls. The arginine is asso-
ciated with defective function – i.e. the defective version is more 
common in controls (it is protective), though, as in other studies, 
it is worth remembering that a majority of AS patients (60%) still 
have ERAP1 molecules with the “defective” R528. This new report 
would appear to comprehensively contradict the previous findings, 
and the explanation for the differences between the two studies is 
not yet clear.
The effects of decreasing ERAP1 function in vitro
Studies on the effects of in vitro silencing of ERAP1 expression, 
to mimic the effects of hypofunctional alleles such as R528K, have 
also reported disparate findings. Chen et al.11 showed a decrease in 
expression of B27 free heavy chains at the cell surface in mono-
cytes of AS patients carrying protective alleles and therefore likely 
a decrease in heavy chain multimers, though this was not shown 
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directly. Importantly, silencing ERAP1 in particular B27-trans-
fected APCs (HeLa and C1R cells) had the expected functional 
effects of lower levels of multimer expression. Multimer expres-
sion engages KIR (specifically KIR3DL2) on T cells and NK cells, 
increasing IL-17 production by T cells and survival of NK cells. 
When ERAP was silenced, both T cell IL-17 production and NK 
cell survival decreased. Perhaps unexpectedly, these results suggest 
that effective ERAP1 function, and hence optimal peptide loading 
of B27 molecules, leads to more expression of the forms of B27 
that can be recognised by KIR3DL2 on T cells and NK cells. The 
result raises the possibility of treating AS by inhibiting ERAP1, i.e. 
mimicking the effects of the hypofunctional protective alleles.
In contrast, Tran et al.12 reported that knockdown of ERAP1 expres-
sion led to greater expression of surface B27 dimers, although 
these experiments were carried out in U937 cells, a more typical 
monocyte-like APC line. Which of these contrasting findings on the 
effects of decreased ERAP1 expression applies physiologically is 
unknown. It will depend on the type and situation of the critical 
APC involved in AS pathogenesis. If this is more like U937, the 
results of Tran et al. would speak against a role for the expression 
of surface B27 multimers in pathogenesis (since protective ERAP1 
alleles increase their expression). Conversely, if an APC in the gut 
or even enthesis has properties more similar to the cells used by 
Chen et al., B27 multimers might still play an important role.
The stimulus to IL-23 production in spondyloarthritis
The most common stimulus to IL-23 production is the interaction 
between APCs and micro-organisms, whether pathogens or normal 
flora. Thus, in SpA there may be an encounter with a pathogen (e.g. 
Salmonella), as seen in reactive arthritis, or an alteration in the rela-
tionship between normal bacterial flora and APCs in the context of 
gut or skin inflammation, as seen in SpA associated with inflam-
matory bowel disease and psoriasis, respectively. There has been 
a great deal of speculation about the role of the microbiome, espe-
cially the gut microbiome, in the pathogenesis of AS, given the high 
proportion of patients with subclinical gut inflammation.
The microbiome in an animal model of SpA
An opportunity to monitor changes in the gut flora as SpA 
evolves is given by the B27 transgenic (B27tg) rat, which over-
expresses human B27 heavy chain and β2 microglobulin and 
develops many features of SpA, especially inflammatory bowel 
disease and arthritis/enthesopathy. Asquith et al.13 recently ana-
lysed caecal microbiota sequentially from weaning to develop-
ment of colitis and arthritis. Changes between wild-type and 
B27tg rats’ microbiota were first evident at 10 weeks, around the 
time that colitis develops. There were increases in certain bacte-
rial species (Proteobacteria and Akkermansia muciniphila) with 
decreases in others (Firmicutes). At early time points (3 weeks 
post weaning), the bacterial flora in both wild-type and B27tg 
littermates resembled the abnormal flora already noted in adult 
B27tg rats, and this reflected the fact that they were all bred from 
B27tg mothers and therefore initially inherited their maternal 
flora. However, this potentially abnormal flora did not persist 
in any rats at 6 weeks. Thus, some feature of the expression of 
B27 led to changes in the microbiota by 10 weeks, and analysis of 
cytokine mRNA expression in the gut revealed increases in TNFα 
and IL-1β, together with increases in anti-microbial peptides. This 
was before any colitis or changes in microbiota were observed. 
Hence, it appeared that over-expression of B27 led to an exagger-
ated gut inflammatory response, which in turn altered the micro-
biota and allowed colitis to develop. At these later stages, increased 
expression of IL-23 and IL-17 were evident, initially in the gut 
mucosa and later the draining lymph nodes, perhaps driven by 
the altered microbiota or amplified by them. A. muciniphila was 
particularly highlighted in this respect, since local expression of 
IL-23, IL-17, and IFNγ correlated with levels of this organism. 
Elevated levels of this organism were also seen in rats develop-
ing arthritis as compared to those that did not. Although increased 
carriage of this organism has also been reported in some SpA 
patients, its aetiologic role in SpA is not clear, and its presence 
might simply be a marker of gut inflammation.
The microbiome in human SpA
Whilst there are relatively few available data on the microbiome 
in human SpA, one study in 2015 showed clear differences in the 
microbial population of the terminal ileum of early AS patients 
when compared to healthy controls14. There was a higher abun-
dance of five families of bacteria, some of which have previously 
been associated with colitis and Crohn’s disease (CD). In relation 
to CD, a very recent report compared a group of patients with CD 
who were divided into those with or without arthritis15; those with 
arthritis had average BASDAI scores of >4. All patients had active 
bowel disease, had not received recent antibiotics, and had intact 
ileocaecal valves. Interestingly, patients who were HLA-B27+ were 
excluded from the group, apparently to decrease the proportion 
with axial SpA, though of course only 50% of those with CD and 
axial SpA will be B27+, and no radiographic data on sacroiliitis 
were presented. Using 16S rRNA sequencing of faecal bacteria did 
not reveal differences between the two groups, though CD patients 
differed from those with ulcerative colitis. However, when instead 
bacteria that had acquired a coating of IgA were investigated, there 
was an increase in the abundance of Enterobacteriaceae in patients 
with arthritis, and specifically of adherent-invasive strains of 
Escherichia coli. Whilst the result was statistically significant, the 
difference was largely due to much higher levels in approximately 
one-third of those with arthritis. It has previously been shown that 
IgA coating of bacteria is a good marker of those species within 
the gut flora that have engaged the attention of the immune system 
and are therefore more likely to be pathogenic. Additional evidence 
of the possible effects of these strains of E. coli came from studies 
in mice in which the bacteria were shown to exacerbate various 
IL-23-driven pathologies, including arthritis and colitis. This is a 
provocative and initial report, and it will be interesting to see the 
same approach applied to additional cohorts of SpA patients. SpA 
has long been associated with elevated levels of IgA, with raised 
IgA specific for the enteric triggers of reactive arthritis being espe-
cially notable.
Conclusions
Together, the selection of recent papers that I have highlighted in 
this review shed additional light on the current central hypotheses 
on the pathology of SpA. They provide important additional evi-
dence of an IL-23-responsive cell in the enthesis, clarify the role 
of ERAP1 polymorphisms in susceptibility to SpA, and investigate 
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the possible implications of those polymorphisms for HLA-B27 
assembly and expression. Lastly, the interplay between B27 
expression and microbiota has been examined in one of the most 
compelling animal models of human SpA, whilst other reports have 
provided additional hints of the role of the microbiota in human 
SpA. Further developments on each of these aspects are likely to 
follow soon and are eagerly awaited.
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